hormona glp 1 y gip Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? CLASIFICACIÓN GLP-1 QUE DEBES RECORDAR🔥

Statements Author contributions SM: Writing original draft

The report projects that sales of orforglipron will reach $16 billion in 2031, whereas retatrutide will produce revenue of $30 billion that year, which includes $10 billion in obesity drug sales and $20 billion in diabetes drug sales

For Research Use Only Not for human consumption

This landscape features major pharmaceutical companies developing GLP-1 therapies, service providers supporting clinical trials, regulatory agencies overseeing safety and efficacy, and end users such as hospitals, clinics, and home care settings

[DOI] [PubMed] [Google Scholar] 160.Borra M.T., Smith B.C., Denu J.M

It is which approach is most appropriate given their metabolic profile, health history, and clinical objectives